Chordoma Foundation TBX Challenge Awards

So, uh, we're gonna start off recognizing some future clinical contributions, and I'm really excited to actually have a kind of late breaking addition to the agenda, um, and a, an award that we were not anticipating getting to make, uh, published at all just, uh, less than a week ago. And we give a little bit of a story to give you background of this report. I think probably everyone in this room has heard the word rackier. It is now the defining Hallmark and diagnostic, the diagnostic hallmark of Corona. I remember first hearing about draft year when I was recovering after surgery in the hospital. I just heard about this thing that I was in the programma, and sort of I went beautiful programs which I have been after. Uh, uh, what came out of the model is part of the business public in May 2006, and part of this, the business published in March 2006. Um, by exputing Uh, in London, the Unified Bay College, who had made this 20% discovery that Ouroma, unlike other SOBA tumors, has this unique characteristic of Right here. Inclusive every single tumor. So the fact that Koroma is now the kind of obvious diagnostic hallmark of Koroma has just been discovered back then in 2006. So, uh, fact forward over the years, we've learned that track meter is not only the diagnostic monitor of production, but layer after layer of evidence, um, presented by our future workshop over the years, it's called. And it's no doubt a story, um, that, uh, has become very clear. Not only is the crap drive in the dynamic computer, but it also is the key vulnerability of forama. And it's it's not only the vulnerability of us, but it differentiates for normal tissue and from other tumor types. The forama does depend on drive the area for their survival. And this grows is an incredible opportunity. Here you have this. Um, proteins that is present in the front uniformly critical for the survival, but not present in normal systems. So from a therapeutic perspective, this is a rare head of opportunities. The problem, and an obvious halfholder templates develop better, the problem is if right here is heading right here is Um, within, um, a typical mass attractive, the type of protein is possibly when this help is developing that drug method. And without going to reveal the ODL, essentially because the structure of this protein doesn't have kind of sockets or loot, uh, that a drug can attack it. Um And actually, those groups we may have, uh, maybe we call back in 20, uh, and eighteen, um, uh, we awarded, uh, the oncoming inside award to a researcher, um, also from the UK and Oprah Julian, who made one of the first advances along with Asian Brewery this year, uh, since being, uh, made one of the first key advances. Um, to kind of break down the intractability of direct period. They install the structure of the person. They figured out what it actually looks like. And overall, the burns, the featured on the person that it looks like in the drug cost. And we, and, and so that was kind of a jumping offline. Now all of a sudden, uh, maybe you can apply some new technologies to as well. Uh, against such a forest fire. And over the ensuing year, various groups tried, like in brewery and others around the world, um, tried to develop models of combined highly anomalous proteins that they produce throughout growth. And, um, they made progress, but there was a critical threshold that needed to be reached, a critical, um Uh, let's say that, uh, that the company refined proteins to be able to develop the drug. And despite a lot of reduced crime, uh, no longer might be able to. And, and by the way, just put this in perspective, the type of proteins right here is, um, involved proteins are involved with a lot of other humanities, and only about one percent of them, uh, we have Have four months that can find heavily enough to develop the work. This is a problem not just for the direct period of talk about achievement types of. And so we got to come to an extremely important platform to cost, extremely important problems to solve. And some of the direct management in the world that decided to solve it, haven't tried to know that crap. So meanwhile, in the last several years, there's been this kind of proliferation of technologies. I'm sure many of you are aware of what's going on in the world of AI and the promise of AI to, um, to kind of solve impactable, uh, drug discovery problems. In parallel, there's technologies that don't get as much, uh, maybe publicity or attention in the press. There's lots of the data that will have to be in particular. That are enabling the screening of the developing and screening of enormous high arrays of compounds. Um, so that hopefully you make it enough to these compounds that are, diverse enough, maybe you get lucky in the final. So there's all these limitless, limitless completely hundreds of different technologies and approaches that you could be applied. As a small organization, um, you can't And we don't have a good idea at the top of the most likely. So we have very, very clear, uh, problem to solve. Now, another part of the story in the last five years, many of you know that these efforts for MFM is taken to set up our own lab, which serves a number of different functions, but one of which, one of the two functions of the lab. Is to be enabling a primary drug account, about half of the lab does. And so we've created a set of capabilities and resources that are intended to make it easy for companies or researchers to have innovative technology that may pick up solid directly problems to highlight to this partners. So okay, now we've built these capabilities. How do we get Companies and researchers have all these technologies to apply them to this town. And that's the opportunity town. Okay, well, what if we go to this town and offer a financial incentive, and we would do that? Maybe people come out of the woodwork that we would never have imagined. Let's see, we could be Technologies that support to be able to solve this kind of problem actually since so many of you may have seen, um, about eighteen months ago we launched called the CBXT town, where we invite companies and researchers, regardless of where they are anywhere in the world, new technology to design and produce chemical compounds that then get sent to our lab in North Carolina. And I team the lab, um, who's here, and maybe they can raise their hand, um, CFLA team. Um, uh, there they are moving up in the back. Uh, this is a team that works day in and day out, um, on behalf of various balls of the world to move forever reason forward to think of me and, um, uh, uh, drive the ICR side of the lab. Um, so, so in the end, we had no idea this was gonna turn out whether, uh, you know, whether anyone can be interested. Uh, but in the end, we've been so on away with the level enter, um, as of September 1st of this year, uh, which is the, the, uh, the deadline entrance, that twenty-six groups be 26 groups send us small fields including 22 companies and four academic class from nine different groups that, um, some of which maybe are, uh, are obvious that you would, um, expect to be working on it, or we would have gone to, and others were completely unexpected from, um, universities and companies from which were in stealth mode and wouldn't be putting her product. Um, and, um, over the last, uh, couple weeks, we've, um, uh, we've had the excitement of, uh, getting our first kids at a compound that seems very progressive. Um, but science is, um Uh, it's really important in science to replicate your findings, make sure you don't have a story that's resolved. And we, uh, get too excited, uh, about something that is, um, you're ready. So the criteria for this, um, this work, the compound has to be tested at least three times the value that to be, um, it was, uh, the last Couple weeks, we came in the last puzzle, really hustle, running in that wild, and repeated, uh, the test now three or four times. And just as of this was last Friday, um, we got the amazing news that there is one compound out of, um, the, uh, more than thousands that have been tested so far in the last That does indeed cross that threshold. Now opening the door potentially to quite a number of new therapy avenues to develop drugs cancer. And we're so fortunate that the team that discovered that wine molecule is here with us today from a company here not far from Boston called ECM. Um, and we're so excited that there, um, the scientist, the scientist and scientist officer, uh, have both joined us for the conference, does an excellent, uh, poster yesterday, um, and have become the first winner of the TBX challenge. So I would like to invite Dennis Finn and Max Wart, uh, from ECATAM to receive Uh, please do a meeting you guys and break for two questions. So needless to say, we're extremely excited for so many reasons. We're so grateful to XM, and really, I think Zen deserves a tremendous amount of credit. Um, as I intended, this was a minute to pass the project then. Um, and we're not for him, this was not announced. So, uh, and we're so grateful to you. On behalf of the entire quota community. This is really step one and a lot of work to do. And as it's also interesting that there are multiple prizes to win. So the first prize was intended to reach one critical fresh hole with another even more rigorous or difficult festival that we need to reach. So I believe that Chem is continuing this challenge and it's gonna hopefully, uh, reach within additional combat, optimized compounds to reach that fresh hole. But there's also three prizes, and so potentially others win as well. And the idea is to run multiple shots on goal. There's, as I said, multiple limits there to be like opportunities that could, um, that could flow from this. So, um, this now just opens up, uh, the doors to a lot of important work ahead that we are excited, uh, the foundation to support and, uh, and drive forward. So just a huge victory for this community, for the research community, for the patient community, and we reached this, uh, and so excited and so very important. Um, thank you so much for what you did.